Thus, suppressing EGFR and CASP3 may alleviate pulmonary disease and fibrosis, as well as thrombotic events and leukopenia, respectively, which play a significant part in the pathophysiology of COVID-19 (Figure 14). The gene discussed is EGFR; the disease is Decreased total leukocyte count.